Attorney Docket No.: 6246.200-US

TECH CENTER 1600/2900 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: P. Serup et al

Application No.: 10/090,011

Group Art Unit: 1653

Filed: February 26, 2002

Examiner: To be assigned

Confirmation No: 3868

For: Methods for Generating Insulin-Secreting Cells Suitable For Transplantation

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, DC 20231

Sir:

MAR 0 6 2003

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith a reference which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the reference may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the reference is "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The reference is listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the reference is also enclosed. The reference is as follows:

> 1. WO 99/35245

It is respectfully requested that this reference be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached reference.

The supplemental information disclosure statement submitted herewith is being filed **before** the mailing date of a first Office action on the merits. Therefore, no fee is due.

Respectfully submitted,

Date: March 3, 2003

Richard W. Bork, Reg. No. 36,459 Novo Nordisk Pharmaceuticals, Inc. 100 College Road West Princeton, NJ 08540 (609) 987-5800

23650
PATENT TRADEMARK OFFICE

MAR 0 6 2003 R MAR 0 6 2003 R ADEMAN Attorney Docket No.: 6246.200-US PACENT O 2003
ARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: P. Serup et al

Serial No.: 10/090,011

Group Art Unit: 1653

Filed: February 26, 2002

Examiner: To be assigned

Confirmation No: 3868

For: Methods for Generating Insulin-Secreting Cells Suitable For Transplantation

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

- 1. Supplemental Information Disclosure Statement
- 2. Form PTO-1449
- 3. Copy of Reference

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents Washington, DC 20231

on March 3, 2003

Rashida Haji

(name of person mailing paper)

(signature of person mailing paper)

		.				Sh	eet 1 of 1	
Rev. 2-3270	U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE			Atty. Docket No. 6246.200-US		Serial No. 10/090,011		
e ma is	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant P. Serup et al					
AR O 6 2003 P			Filing Date February 26, 2002		Group 1653			
TARK!		U.S. PATE	ENT DOCUMENTS					
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING IF APPRO		
					P			
					8 1	CE	VED	
					МД	R 1 0 2	102	
					TECHA	R 1 0 2003		
					'EVITUE	ITER 1600/2900		
		FOREIGN PA	ATENT DOCUMENTS			<u> </u>		
	DOCUMENT				1	TRANSLATION		
	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO _	
	WO 99 35245	7/15/99	PCT			х		
			, , , , , , , , , , , , , , , , , , , ,					
					<u> </u>		l	
	OTHER	DOCUMENTS (Includin	g Author, Title, Date, Pe	rtinent Pages, E	tc.)			
				.,,				

DATE CONSIDERED EXAMINER EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.